# The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

> **NCT05885399** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 5 (estimated)

## Conditions studied

- Pheochromocytoma, Metastatic
- Pheochromocytoma Malignant
- Paraganglioma, Malignant

## Interventions

- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT05885399
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885399, "The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05885399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*